Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Millipore Corporation and Novozymes Form Strategic Alliance to Supply Animal-Free Cell Culture Supplements for Bioprocessing

Published: Tuesday, December 18, 2007
Last Updated: Tuesday, December 18, 2007
Bookmark and Share
Alliance will accelerate launch of new animal-free supplements and provide customers with a source of high performance cell culture products.

Millipore Corporation and Novozymes have announced an agreement to develop, market, and sell new, animal-free cell culture supplements for biopharmaceutical manufacturing.

The new products, to be marketed under the brand name CellPrime™, will be manufactured by Novozymes and sold through Millipore’s sales organization. The alliance expands the existing relationship between Millipore and Novozymes and will initially focus on developing recombinant human albumin and recombinant human transferrin.

Cell culture supplements help mammalian cells produce the proteins that form the basis of biologic drugs. Today, customers seeking to utilize defined, animal-free supplements in their biopharmaceutical production processes have limited options. The CellPrime™ products are designed to reduce risk and ease regulatory concerns for biopharmaceutical manufacturers. Additionally, these products will help to improve the consistency and productivity of customers’ industrial cell culture processes.

“Our expanded relationship with Novozymes broadens our commitment to develop a portfolio of high quality, animal-free alternatives that optimize productivity, address drug safety, and ease regulatory approval,” said Andrew Bulpin, Ph.D., Vice President of Millipore’s Upstream Bioprocessing Business Unit.

“Our CellPrime™ products will give customers a reliable, long-term supply of regulatory compliant supplements and address their desire to eliminate the use of animal-derived products in their manufacturing processes,” Mr. Bulpin continued.

“We are excited about expanding our relationship with Millipore given the company’s leading position in serving the biopharmaceutical manufacturing market,” said Peter Rosholm, Vice President of Novozymes Biopharma.

“By leveraging the strengths of both companies, we will accelerate the introduction and adoption of innovative new products and enable our customers’ to re-think their production processes. This collaboration further strengthens our position as a strategic partner for biopharmaceutical companies and broadens Novozymes’ biopharmaceutical product portfolio.”

The process of manufacturing biologic drugs such as monoclonal antibodies begins with growing mammalian cells in a bioreactor. These cells are cultured in media and require the addition of supplements to enable efficient production of therapeutic proteins that form the basis of biologic drugs.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cellular Reprogramming – What the Future Holds
Advancements in cellular reprogramming are coming at a furious pace. Along with these scientific breakthroughs come new opportunities for the development of therapeutics, disease modeling, drug screening, and new pathways to personalized medicine.
Friday, July 23, 2010
Millipore Expands Drug Discovery and Development Services with BioAnaLab Acquisition
Acquisition extends Millipore’s biopharmaceutical services offering to European market.
Tuesday, August 11, 2009
Millipore Opens new Bioprocess Manufacturing Facility in Massachusetts
New facility will produce company’s Mobius® single-use product line used for biopharmaceutical manufacturing technologies.
Wednesday, June 10, 2009
Millipore and UMass Lowell Dedicate the Millipore Process Development Laboratory
Millipore announced the opening of the Millipore Corporation Process Development Laboratory in partnership with the university.
Friday, April 10, 2009
Millipore Announces Technology Acquisition to Strengthen Drug Discovery Product Offering
The purchase of Epitome Biosystems’ EpiTag™ technology assets will accelerate development of multiplex immunoassays for cell signaling.
Monday, March 02, 2009
Millipore Extends Exclusive License Agreement with University of Dundee
The ongoing collaboration will bring novel cell signaling tools and services to life science researchers worldwide.
Friday, October 10, 2008
ReNcell® VM Neural Stem Cell Line Models Parkinson’s Disease
Milipore announces the publication of a new discovery derived from its ReNcell VM neural stem cell line.
Tuesday, July 22, 2008
Millipore Unveils Expanded Drug Discovery Development Facility
The $3.4 million expansion will enable Millipore to keep pace with the growth of its worldwide drug discovery and development business.
Monday, June 30, 2008
Millipore Launches Progenitor Cell-Enriched Primary Human Epithelial Cell Cultures
According to Company, these primary cell cultures are designed to provide an enriched population of progenitor cells from skin, cornea, and bladder epithelia.
Friday, April 18, 2008
Millipore Launches Antibody Learning Center
The web tool is designed for navigating company’s antibody portfolio and planning efficient workflows for immunodetection in protein research.
Wednesday, April 16, 2008
Frost & Sullivan Commends Millipore’s Success in Developing Mammalian Gene Expression UCOE Technology
Millipore announced to be the recipient of the 2007 Frost & Sullivan Technology Innovation of the Year Award in the U.S. Drug Discovery Technologies market.
Monday, December 10, 2007
Millipore Announces Stem Cell Tested Initiative
Millipore’s Stericup with Express PLUS membrane is the first available under this initiative.
Wednesday, December 05, 2007
Millipore Launches new Website
Improved functions include product information, ordering and support.
Wednesday, October 31, 2007
Millipore Corporation Announces new ReNcell® Data from Collaboration with ReNeuron
Millipore releases new data concerning its ReNcell neural stem cell lines at the ISSCR meeting in Cairns, Australia on June 20, 2007.
Thursday, June 21, 2007
Millipore Announces Kinase Screening Agreement with Johnson & Johnson Pharmaceutical Research & Development
J&JPRD to supply potential protein kinase inhibitors for kinase selectivity profiling against Millipore's panel of 252 protein and lipid kinases.
Wednesday, January 17, 2007
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Researchers Develop Software That Could Facilitate Drug Development
AptaTRACE can identify aptamers, potentially speed drug advancement.
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
New Medication Shows Promise Against Liver Fibrosis in Animal Studies
Liver fibrosis is a gradual scarring of the liver that puts people at risk for progressive liver disease and liver failure.
Raw Eggs Deemed Safe to Eat
A report published today by the Advisory Committee on the Microbiological Safety of Food (ACMSF) into egg safety has shown a major reduction in the risk from salmonella in UK eggs.
Monitoring TTX Toxin in Shellfish
In a number of small studies, mussels and oysters from the eastern and northern part of the Oosterschelde in Holland were found to contain tetrodotoxin (TTX).
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!